These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 26391155

  • 1. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
    You B, Salles G, Bachy E, Casasnovas O, Tilly H, Ribrag V, Sebban C, Hénin E, Guitton J, Tod M, Freyer G.
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):939-48. PubMed ID: 26391155
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L, Vidriales B, del Cañizo MC, Corral M, Gonzalez M, León A, Jean-Paul E, Rocha E, Moraleda JM, San Miguel JF.
    Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
    William BM, Loberiza FR, Whalen V, Bierman PJ, Bociek RG, Vose JM, Armitage JO.
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
    Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A.
    Cancer; 2012 Oct 01; 118(19):4706-14. PubMed ID: 22252613
    [Abstract] [Full Text] [Related]

  • 10. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):208-18. PubMed ID: 15093918
    [Abstract] [Full Text] [Related]

  • 11. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH, Kuhlmann M, Demant A, Krug U, Thoennissen GB, Schmidt E, Kessler T, Schliemann C, Pohlen M, Mohr M, Evers G, Köhler G, Wessling J, Mesters R, Müller-Tidow C, Berdel WE, Thoennissen NH.
    Ann Hematol; 2013 Aug 01; 92(8):1041-8. PubMed ID: 23532626
    [Abstract] [Full Text] [Related]

  • 12. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
    Kruger PC, Cooney JP, Turner JH.
    Cancer Biother Radiopharm; 2012 Nov 01; 27(9):552-60. PubMed ID: 23062193
    [Abstract] [Full Text] [Related]

  • 13. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
    Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS, Park CJ, Huh J, Suh C.
    Leuk Res; 2011 Feb 01; 35(2):183-7. PubMed ID: 20684990
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM, Allen MS, Loberiza FR, Bociek RG, Bierman PJ, Armitage JO, Vose JM.
    Biol Blood Marrow Transplant; 2014 Apr 01; 20(4):536-42. PubMed ID: 24434781
    [Abstract] [Full Text] [Related]

  • 16. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
    Clavio M, Garrone A, Pierri I, Michelis GL, Balocco M, Albarello A, Varaldo R, Canepa P, Miglino M, Ballerini F, Canepa L, Gobbi M.
    Oncol Rep; 2005 Oct 01; 14(4):933-40. PubMed ID: 16142354
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
    Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC, Armitage JO.
    J Clin Oncol; 2005 Jan 20; 23(3):461-7. PubMed ID: 15534357
    [Abstract] [Full Text] [Related]

  • 19. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO).
    Eur J Haematol; 2008 Mar 20; 80(3):227-35. PubMed ID: 18088400
    [Abstract] [Full Text] [Related]

  • 20. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group.
    J Clin Oncol; 2005 Jun 01; 23(16):3793-801. PubMed ID: 15809447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.